CALQUENCE® (acalabrutinib) ELEVATE-TN, Including 6-Year Median Follow-Up Data – Dr O’ Brien, MD
20:01
CALQUENCE® (acalabrutinib) MAIC of ASCEND and ALPINE – Dr Skarbnik, MD
18:35
CALQUENCE® (acalabrutinib) ACE-CL-001 (ibrutinib-intolerant cohort) – Dr Raval, MD
19:00
CALQUENCE® (acalabrutinib) ELEVATE-RR and ASCEND Data – Dr Ma, MD
15:59
CALQUENCE® (acalabrutinib) Long-Term Data – Dr Brem, MD
15:22
CALQUENCE® (acalabrutinib) ELEVATE-TN data, incl. High-Risk Subgroups – Dr Abutalib, MD
14:09
CALQUENCE® (acalabrutinib) Safety Data – Dr Levy, MD
12:20
CALQUENCE® (acalabrutinib) Perspectives: Dr Alexey Danilov, MD, PhD
9:28